Clinical characteristics of GATA2 ASE and GATA2 non-ASE groups
| Group . | % (n) . | P* . | Effect size (CI)*† . | |
|---|---|---|---|---|
| GATA2 ASE (n = 103) . | GATA2 non-ASE (n = 67) . | |||
| Sex | .34 | 0.72 (0.36-1.4) | ||
| Female | 48 (49) | 39 (26) | ||
| Male | 49 (50) | 55 (37) | ||
| Missing | 3.9 (4) | 6 (4) | ||
| Age, y | .79 | −0.19 (−0.51 to 0.13) | ||
| Median | 48.00 | 47.00 | ||
| MAD | 17.79 | 19.27 | ||
| Mean, % | 48.70 | 45.57 | ||
| SD, % | 16.82 | 16.30 | ||
| Range | 15-86 | 17-77 | ||
| Missing | 3.9 (4) | 6.0 (4) | ||
| ELN classification | .22 | 0.14 (0-0.28) | ||
| Adverse | 20 (21) | 30 (20) | ||
| Favorable | 50 (52) | 37 (25) | ||
| Intermediate | 28 (29) | 27 (18) | ||
| Missing | 0.97 (1) | 6 (4) | ||
| WBC count | .28 | 0.29 (−0.065 to 0.64) | ||
| Median | 43.00 | 62.00 | ||
| MAD | 35.88 | 52.19 | ||
| Mean, % | 60.14 | 78.29 | ||
| SD, % | 50.10 | 80.29 | ||
| Range | 1-215 | 0-510 | ||
| Missing | 15.5 (16) | 26.9 (18) | ||
| NPM1 | .005 | 2.7 (1.3-6) | ||
| Negative | 58 (60) | 79 (53) | ||
| Positive | 42 (43) | 21 (14) | ||
| FLT3-ITD | .0068 | 2.7 (1.3-6.2) | ||
| Negative | 60 (62) | 81 (54) | ||
| Positive | 40 (41) | 19 (13) | ||
| CEBPA DMs | <.001 | NA (4 to NA) | ||
| Negative | 80 (82) | 100 (67) | ||
| Positive | 20 (21) | |||
| CEBPA SMs | 1 | 0.86 (0.14-6.1) | ||
| Negative | 96 (99) | 96 (64) | ||
| Positive | 3.9 (4) | 4.5 (3) | ||
| CEBPA silenced | .75 | 0.77 (0.19-3.3) | ||
| Negative | 94 (97) | 93 (62) | ||
| Positive | 5.8 (6) | 7.5 (5) | ||
| t(15;17) | .079 | 0.16 (0.0031-1.6) | ||
| Negative | 99 (102) | 94 (63) | ||
| Positive | 0.97 (1) | 6 (4) | ||
| t(8;21) | .036 | 0.12 (0.0026-1.1) | ||
| Negative | 99 (102) | 93 (62) | ||
| Positive | 0.97 (1) | 7.5 (5) | ||
| inv(16) | .1 | 0.4 (0.11-1.3) | ||
| Negative | 94 (97) | 87 (58) | ||
| Positive | 5.8 (6) | 13 (9) | ||
| Normal karyotype | <.001 | 4.4 (2.1-9.7) | ||
| Negative | 36 (37) | 67 (45) | ||
| Positive | 57 (59) | 24 (16) | ||
| Missing | 6.8 (7) | 9 (6) | ||
| Complex karyotype | .73 | 0.75 (0.15-4) | ||
| Negative | 70 (72) | 64 (43) | ||
| Positive | 4.9 (5) | 6 (4) | ||
| Missing | 25 (26) | 30 (20) | ||
| Group . | % (n) . | P* . | Effect size (CI)*† . | |
|---|---|---|---|---|
| GATA2 ASE (n = 103) . | GATA2 non-ASE (n = 67) . | |||
| Sex | .34 | 0.72 (0.36-1.4) | ||
| Female | 48 (49) | 39 (26) | ||
| Male | 49 (50) | 55 (37) | ||
| Missing | 3.9 (4) | 6 (4) | ||
| Age, y | .79 | −0.19 (−0.51 to 0.13) | ||
| Median | 48.00 | 47.00 | ||
| MAD | 17.79 | 19.27 | ||
| Mean, % | 48.70 | 45.57 | ||
| SD, % | 16.82 | 16.30 | ||
| Range | 15-86 | 17-77 | ||
| Missing | 3.9 (4) | 6.0 (4) | ||
| ELN classification | .22 | 0.14 (0-0.28) | ||
| Adverse | 20 (21) | 30 (20) | ||
| Favorable | 50 (52) | 37 (25) | ||
| Intermediate | 28 (29) | 27 (18) | ||
| Missing | 0.97 (1) | 6 (4) | ||
| WBC count | .28 | 0.29 (−0.065 to 0.64) | ||
| Median | 43.00 | 62.00 | ||
| MAD | 35.88 | 52.19 | ||
| Mean, % | 60.14 | 78.29 | ||
| SD, % | 50.10 | 80.29 | ||
| Range | 1-215 | 0-510 | ||
| Missing | 15.5 (16) | 26.9 (18) | ||
| NPM1 | .005 | 2.7 (1.3-6) | ||
| Negative | 58 (60) | 79 (53) | ||
| Positive | 42 (43) | 21 (14) | ||
| FLT3-ITD | .0068 | 2.7 (1.3-6.2) | ||
| Negative | 60 (62) | 81 (54) | ||
| Positive | 40 (41) | 19 (13) | ||
| CEBPA DMs | <.001 | NA (4 to NA) | ||
| Negative | 80 (82) | 100 (67) | ||
| Positive | 20 (21) | |||
| CEBPA SMs | 1 | 0.86 (0.14-6.1) | ||
| Negative | 96 (99) | 96 (64) | ||
| Positive | 3.9 (4) | 4.5 (3) | ||
| CEBPA silenced | .75 | 0.77 (0.19-3.3) | ||
| Negative | 94 (97) | 93 (62) | ||
| Positive | 5.8 (6) | 7.5 (5) | ||
| t(15;17) | .079 | 0.16 (0.0031-1.6) | ||
| Negative | 99 (102) | 94 (63) | ||
| Positive | 0.97 (1) | 6 (4) | ||
| t(8;21) | .036 | 0.12 (0.0026-1.1) | ||
| Negative | 99 (102) | 93 (62) | ||
| Positive | 0.97 (1) | 7.5 (5) | ||
| inv(16) | .1 | 0.4 (0.11-1.3) | ||
| Negative | 94 (97) | 87 (58) | ||
| Positive | 5.8 (6) | 13 (9) | ||
| Normal karyotype | <.001 | 4.4 (2.1-9.7) | ||
| Negative | 36 (37) | 67 (45) | ||
| Positive | 57 (59) | 24 (16) | ||
| Missing | 6.8 (7) | 9 (6) | ||
| Complex karyotype | .73 | 0.75 (0.15-4) | ||
| Negative | 70 (72) | 64 (43) | ||
| Positive | 4.9 (5) | 6 (4) | ||
| Missing | 25 (26) | 30 (20) | ||
Descriptive statistics and hypotheses tests were computed for patients with AML with or without GATA2 ASE using Atable.
CI, confidence interval; ELN, European LeukemiaNet; ITD, internal tandem duplication; MAD, median absolute deviation; NA, not available; SD, standard deviation; SM, single mutation; WBC, white blood cell.
Reflects evaluation of the association between groups with or without GATA ASE and clinical variables.
Effect size measured as odds ratio for categorical variables and Cohen’s D for numerical variables.